Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID-19: An early phase 1 descriptive study.

ABSTRACT:

Background

At the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, transfusion of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) emerged as a potential therapeutic strategy to help patients severely afflicted by COVID-19. The efficacy of CCP has been controversial as it depends on many variables pertaining to the plasma donor and the patient with COVID-19, for example, time of convalescence or symptoms onset. This feasibility and descriptive study aimed to assess the safety of multiple doses of CCP in mechanically ventilated, intubated patients with respiratory failure due to COVID-19.

Methods

A cohort of 30 patients all experiencing severe respiratory failure and undergoing invasive mechanical ventilation in an intensive

SUBMITTER: Aguilar R 

PROVIDER: S-EPMC10920941 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature